Granuloma annulare is an anatomo-clinical entity that is frequently encountered in everyday dermatological practice. We report our experience regarding 4 patients with disseminated granuloma annulare. Each patient was treated with a cycle of cyclosporine therapy for six weeks. A cycle of systemic cyclosporine therapy was started at a dose of 4 mg/kg/day for four weeks, subsequently reduced by 0.5 mg/kg/day every two weeks. The clinical picture more or less completely resolved within three weeks in all of the patients, and there were no relapses during the dose-tapering period or the following 12 months. Cyclosporine was optimally tolerated by all four patients, none of whom experienced any therapy-related side effects. Cyclosporine is a valid therapeutic option for the treatment of disseminated granuloma annulare, although we recommend its use in a protected hospital environment that facilitates patient monitoring.
Granuloma annulare is an anatomic-clinical entity that is frequently encountered in everyday dermatological practice. Its typical clinical form manifests itself as normally coloured or pinkish papulonodular lesions grouped in centrifugally distributed rings. Its histological counterpart is a palisading granuloma surrounding foci of dermohypodermal connective tissue degeneration. The best-known of its numerous clinical variants is disseminated or generalised granuloma annulare in which, in addition to its marked skin involvement, one may find an association with diabetes mellitus.
It needs to be underlined that granuloma annulare is an asymptomatic, benign condition with an unpredictable course that often spontaneously heals within a period of 2-3 years. It must therefore be treated in an absolutely conservative manner -to the point that it is often not treated at all. However, therapy is required because of the psychological status of the patient and the clinical involvement of the generalised forms.
MATERIALS AND METHODS
During the course of one year, one male and three female patients with disseminated granuloma annulare were brought to our attention, all of whom were treated with cyclosporine.
Case No. I. The first patient was a 63-year-old woman, whose lesions had appeared about four years previously and had been unsuccessfully treated with mediumhigh strength topical steroids. Her clinical picture was characterised by erythematous papulonodular lesions, which were distributed in centrifugal rings on her limbs, abdomen and armpits, and were atypically pruritic.
was more evident at the edges of the plaques, and they were mainly located on her trunk and hands. The patient had been affected by non insulin-dependent diabetes mellitus for about two years and had been successfully treated with oral glycemia-lowering agents for about eight months.
Case No.3. The third patient was a 47-year-old man who had been affected for about one year by very slight erythematous papulonodular lesions with pinkish, infiltrated borders in a typical ring-shaped pattern on his trunk, legs and hands. During the course of the disease he had been treated with highly potent topical steroids and systemic steroids without benefit.
Case No.4. The fourth patient, a 61-year-old woman, had been affected for about three years by papular lesions distributed in centrifugal rings on her trunk, elbows and legs. This patient had never been on medication.
RESULTS
Skin examinations permitted a straightforward clinical diagnosis of granuloma annulare in all four cases, which was confirmed by the histological analysis of skin biopsies. The results of routine blood tests were substantially normal, including the glycated hemoglobin values of the diabetic patient. On the basis of published reports (1-3) and our own previous sporadic experiences, a cycle of systemic cyclosporine therapy was started at a dose of 4 mg/kg/day for four weeks, subsequently reduced by 0.5 mg/kg/day every two weeks. The patients were monitored throughout the treatment period for their blood pressure and renal function, which remained normal in all cases.
The clinical picture was more or less completely resolved within three weeks in all of the patients and there were no relapses during the dose-tapering period or the following 12 months. Cyclosporine was optimally tolerated by all four patients, none of whom experienced any therapy-related side effects.
DISCUSSION
The differential diagnosis of granuloma annulare requires knowledge of a large number of granulomatous and non-granulomatous diseases, bearing in mind that disseminated granuloma annulare represents only one of many morphological variants.
Its differential histological diagnosis can sometimes be even more difficult as it requires distinguishing the various types of palisading granulomas.
These aspectsare summarisedin Tables I, II and III. These tables do not need any particular comment but it is worth remembering that, in some cases, the absence of a typical annular appearance or the presence of not better specifiable palisading granulomas can respectively make a differential clinical or histological diagnosis extremely difficult, if not impossible. Furthermore, in clinical terms, it can be pointed out that the correction of endocrine disorders (in our case, and typically, diabetes) does not necessarily prevent the formation of a granuloma annulare or condition its resolution. However, once the diagnosis has been made, there remains the problem of therapeutic decision-making, which is still not based on the large numbers provided by controlled trials, but only on small case series and anecdotal reports.
Many therapies have been suggested for the treatment of granuloma annulare: local or systemic corticosteroids, PUVA, acitretin, dapsone, UVA-I phototherapy, systemic retinoids and many others (Table IV) . We chose cyclosporine because, although not devoid of systemic effects, it is actually quite manageable if used under the appropriate clinical conditions and if the patient is carefully monitored during the period of administration.
The rationale behind the use of cyclosporine lies in its principal action of suppressing cell-mediated immunity by inhibiting cytokine (particularly interleukin-2) production by activated T-helper lymphocytes (9) . However, the pathogenesis of granulomas may be independent of T lymphocytes (10); indeed, in athymic mice, their formation is due to the production ofcytokines such as TNFa by tissue macrophages (11-12). Although the role of cytokines in granuloma annulare is not fully understood, it can be hypothesised that the therapeutic activity of cyclosporine is not only related to the suppression of cell immunity, but also to the inhibition of cytokine production.
The dose we used (4 mg/kg/day for four weeks, subsequently reduced by 0.5 mg/kg every two weeks) was rapidly effective, and no relapses were observed during the dose-tapering period or the following 12 months of follow-up. We describe our clinical experience regarding four adult patients with disseminated granuloma annulare who came to our attention during the course of one year and were treated in day-hospital with cyclosporine at a dose of 4 mglkg/day for four weeks, followed by reductions of 0.5 mglkg every two weeks. All four patients showed a more or less complete clinical improvement within three weeks, and no relapses were observed during the dose-tapering phase or the subsequent 12 months of follow-up. The systemic cyclosporine therapy was optimally tolerated by all of the subjects, and no blood or pressure alterations were noted during the routine drug monitoring examinations. On the basis of our experience, we suggest that cyclosporine is a valid therapeutic option for the treatment of disseminated granuloma annulare, 
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The eminently local therapies (e.g. drug infiltrations, surgery) originally proposed for the isolated ordinary forms of granuloma annulare can also be applied, alone or in combination with other measures, to selected (resistant, disfiguring ...) lesions ofthe generalisedform.
* Typically diabetes mellitus or hypothyroidism.
although we recommend its use in a protected hospital environment that facilitates patient monitoring.
